CODON-OPTIMIZED RECOMBINANT PLASMID ENCODING VEGF AND FGF-2 AND METHODS TO STIMULATE PERIPHERAL NERVE REGENERATION AND TREAT NERVE DAMAGE IN HUMANS

The invention relates to medicine, and more particularly to neurosurgery and trauma surgery, and can be used for stimulating nerve regeneration through the use of a gene therapeutic construct which codes for vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF-2). The gene the...

Full description

Saved in:
Bibliographic Details
Main Authors RIZVANOV, ALBERT ANATOLYEVICH, SALAFUTDINOV, ILNUR ILDUSOVICH, PLAKSA, IGOR LEONIDOVICH, BOGOV, ANDREI ALEKSEEVICH, MASGUTOV, RUSLAN FARIDOVICH, ISAEV, ARTUR ALEKSANDROVICH, DEEV, ROMAN VADIMOVICH, BOZO, ILYA YADIGEROVICH, BOGOV, ALEKSEI ANDREEVICH
Format Patent
LanguageEnglish
French
Published 25.06.2019
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention relates to medicine, and more particularly to neurosurgery and trauma surgery, and can be used for stimulating nerve regeneration through the use of a gene therapeutic construct which codes for vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF-2). The gene therapeutic construct that codes for the two factors is based on a codon-optimized recombinant plasmid. The gene therapeutic construct can be introduced either directly into a damaged nerve or into the perineural tissues either during surgery or in the post-operative period. The invention significantly improves the outcomes of the reconstructive treatment of damaged peripheral nerves. L'invention concerne la médecine et notamment la neurochirurgie, la traumatologie et peut être utilisée pour stimuler la régénération de nerfs grâce à l'utilisation d'une construction de thérapie génique codant pour le facteur de croissance endothélial codant (VEGF) et le facteur de croissance des fibroblastes (FGF-2). A la base d'une construction de thérapie génique codant pour les deux facteurs on utilise un plasmide recombinant à codon optimisé. L'introduction d'une construction de thérapie génique peut s'effectuer directement dans le nerf endommagé ou dans des tissus paraneuraux, pendant l'opération ou lors de la période postopératoire. L'invention améliorer sensiblement les résultats d'un traitement de reconstruction de nerfs périphériques.
Bibliography:Application Number: CA20152960371